Adhera Therapeutics Performance
| ATRXDelisted Stock | USD 0.72 0.00 0.00% |
The firm shows a Beta (market volatility) of -3.64, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Adhera Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Adhera Therapeutics is expected to outperform it. Adhera Therapeutics right now shows a risk of 0.0%. Please confirm Adhera Therapeutics total risk alpha, as well as the relationship between the downside variance and day median price , to decide if Adhera Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Adhera Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Adhera Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 1000.00 | |
| Free Cash Flow | -665 K |
Adhera |
Adhera Therapeutics Relative Risk vs. Return Landscape
If you would invest 72.00 in Adhera Therapeutics on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Adhera Therapeutics or generate 0.0% return on investment over 90 days. Adhera Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Adhera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adhera Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adhera Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Adhera Therapeutics, and traders can use it to determine the average amount a Adhera Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ATRX |
Based on monthly moving average Adhera Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adhera Therapeutics by adding Adhera Therapeutics to a well-diversified portfolio.
Adhera Therapeutics Fundamentals Growth
Adhera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Adhera Therapeutics, and Adhera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adhera Pink Sheet performance.
| Return On Asset | -4.48 | ||||
| Current Valuation | 10.55 M | ||||
| Shares Outstanding | 3.16 M | ||||
| Price To Earning | (125.83) X | ||||
| Price To Sales | 8.23 X | ||||
| EBITDA | (4.92 M) | ||||
| Cash And Equivalents | 849 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 7.35 M | ||||
| Debt To Equity | 56.30 % | ||||
| Book Value Per Share | (6.90) X | ||||
| Cash Flow From Operations | (665 K) | ||||
| Earnings Per Share | (0.52) X | ||||
| Total Asset | 196 K | ||||
| Retained Earnings | (42.43 M) | ||||
| Current Asset | 20.36 M | ||||
| Current Liabilities | 3.88 M | ||||
About Adhera Therapeutics Performance
Evaluating Adhera Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Adhera Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Adhera Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana. Adhera Therapeutics is traded on OTC Exchange in the United States.Things to note about Adhera Therapeutics performance evaluation
Checking the ongoing alerts about Adhera Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Adhera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adhera Therapeutics is not yet fully synchronised with the market data | |
| Adhera Therapeutics has some characteristics of a very speculative penny stock | |
| Adhera Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Adhera Therapeutics currently holds 7.35 M in liabilities with Debt to Equity (D/E) ratio of 56.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Adhera Therapeutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Adhera Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Adhera Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adhera Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adhera to invest in growth at high rates of return. When we think about Adhera Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (6.35 M) with loss before overhead, payroll, taxes, and interest of (157 K). | |
| Adhera Therapeutics currently holds about 849 K in cash with (665 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 22.0% of Adhera Therapeutics shares are held by company insiders |
- Analyzing Adhera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adhera Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Adhera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adhera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adhera Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adhera Therapeutics' pink sheet. These opinions can provide insight into Adhera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |